Blog

DHEA-S (dehydroepiandrosterone sulfate) is the most abundant adrenal androgen — produced primarily by the adrenal glands. It’s the sulfated form of DHEA, which serves as a precursor for sex hormones. DHEA-S is stable in blood (unlike DHEA which fluctuates), making it the preferred test. Reference ranges vary significantly by age: peak in 20s (300-600 mcg/dL); declines steadily with age (over 70 often under 100). Testing uses: PCOS evaluation, congenital adrenal hyperplasia screening, adrenal tumor workup, adrenal insufficiency evaluation, premature adrenarche in children. Not routinely tested for diabetes. Elevated DHEA-S causes: congenital adrenal hyperplasia (non-classic form most common in adults), PCOS (modest elevation), adrenal tumor (rare; significant elevation), Cushing’s syndrome (some cases), DHEA supplementation. Significantly elevated DHEA-S (over 700 mcg/dL) suggests tumor or major adrenal pathology. PCOS connections: characterized by insulin resistance; many women with PCOS have modestly elevated DHEA-S along with elevated testosterone; treatment (metformin, weight loss, GLP-1 agonists) improves both insulin resistance and androgen excess. DHEA supplementation generally not recommended for diabetes — randomized trials show minimal or no benefit for cognitive function, body composition, or metabolic health; side effects include acne, oily skin, hair growth in women, mood changes; may raise estrogen (cancer history concern); not regulated like medications. For most adults with diabetes, DHEA-S not routinely tested; used in specific clinical situations to evaluate hyperandrogenism or adrenal disorders.

DHEA-S Reference Ranges by Age

Causes of Elevated DHEA-S

• Congenital adrenal hyperplasia (CAH): enzymatic defect; non-classic form most common in adults.
• PCOS: modest elevation along with elevated testosterone.
• Adrenal tumor (rare): significant elevation; often over 700 mcg/dL.
• Cushing’s syndrome (some cases): cortisol excess with associated androgen excess.
• Premature adrenarche: in children — early adrenal androgen production.
• DHEA supplementation: exogenous source.
• Some androgen-secreting tumors: ovarian or adrenal.

Causes of Low DHEA-S

• Aging (natural decline).
• Adrenal insufficiency (Addison’s disease).
• Hypopituitarism — pituitary dysfunction.
• Severe stress or chronic illness.
• Long-term corticosteroid use.
• Anorexia nervosa.
• HIV/AIDS.
• Type 1 diabetes (sometimes associated with relative deficiency).
• Severe depression.
• Chronic kidney disease.

PCOS and DHEA-S

• 30-50% of women with PCOS have modestly elevated DHEA-S.
• Indicates adrenal contribution to hyperandrogenism.
• Often elevated alongside testosterone.
• Treatment same as overall PCOS: weight loss, metformin, OCPs, anti-androgens (spironolactone).
• GLP-1 agonists newer for PCOS — particularly effective.
• Treating insulin resistance often modestly lowers DHEA-S.
• Lifestyle interventions support both metabolic and hormonal improvements.

DHEA Supplementation Considerations

• Available OTC in U.S.; banned in some countries.
• Common doses: 25-100 mg.
• Marketed for “anti-aging,” cognition, libido, metabolic health.
• Evidence: minimal benefits in randomized trials.
• Some evidence for adrenal insufficiency replacement (specialized; low-dose 10-25 mg with provider guidance).
• Side effects: acne, oily skin, hirsutism in women, breast tenderness, mood changes.
• May affect hormone-sensitive cancers — avoid with breast, prostate cancer history.
• Banned by athletic organizations (anabolic precursor).
• Not regulated like medications — quality varies.
• Don’t take without discussing with healthcare provider.

When to Test DHEA-S

• PCOS evaluation (with testosterone, LH/FSH).
• Congenital adrenal hyperplasia screening.
• Hyperandrogenism workup (hirsutism, acne, menstrual irregularities).
• Adrenal tumor evaluation (with imaging).
• Adrenal insufficiency evaluation (with cortisol, ACTH).
• Premature adrenarche in children.
• Unexplained virilization.
• Not routine for diabetes — only when clinical suspicion for adrenal disorder.

Workup Patterns

The Bottom Line

DHEA-S (dehydroepiandrosterone sulfate) is the most abundant adrenal androgen — produced primarily by the adrenal glands’ zona reticularis. It’s the sulfated form of DHEA, which serves as a precursor for sex hormones (testosterone and estrogen). DHEA-S is stable in blood (unlike DHEA which fluctuates), making it the preferred test. Reference ranges vary significantly by age: peak in 20s (300-600 mcg/dL); declines steadily with age (over 70 often under 100). Testing uses: PCOS evaluation, congenital adrenal hyperplasia screening, adrenal tumor workup, adrenal insufficiency evaluation, premature adrenarche in children. Not routinely tested for diabetes. Causes of elevated DHEA-S: congenital adrenal hyperplasia (non-classic form most common in adults), PCOS (modest elevation; 30-50% of women with PCOS), adrenal tumor (rare; significant elevation often over 700 mcg/dL), Cushing’s syndrome (some cases), DHEA supplementation. Causes of low DHEA-S: aging (natural decline), adrenal insufficiency (Addison’s disease), hypopituitarism, severe stress or chronic illness, long-term corticosteroid use, anorexia nervosa, HIV/AIDS, chronic kidney disease. PCOS connections: characterized by insulin resistance; many women with PCOS have modestly elevated DHEA-S along with elevated testosterone; treatment (metformin, weight loss, GLP-1 agonists, OCPs, anti-androgens like spironolactone) improves both insulin resistance and androgen excess. DHEA supplementation considerations: available OTC in U.S.; marketed for “anti-aging,” cognition, libido, metabolic health; evidence shows minimal benefits in randomized trials; specialized use in adrenal insufficiency replacement (low-dose 10-25 mg with provider guidance); side effects include acne, oily skin, hirsutism in women, breast tenderness, mood changes; may affect hormone-sensitive cancers — avoid with breast or prostate cancer history; banned by athletic organizations; not regulated like medications. Don’t take without discussing with healthcare provider. Workup patterns: modest DHEA-S elevation + elevated testosterone = PCOS; significant DHEA-S elevation (over 700) = adrenal tumor (investigate); elevated DHEA-S + elevated 17-OH-progesterone = congenital adrenal hyperplasia; elevated DHEA-S + Cushingoid features = Cushing’s syndrome variant; low DHEA-S + symptoms = Addison’s disease or chronic illness. For most adults with diabetes, DHEA-S not routinely tested; used in specific clinical situations — PCOS evaluation, congenital adrenal hyperplasia screening, hyperandrogenism workup, adrenal tumor or insufficiency evaluation. See our broader diabetes detection guide for context.

Prolactin is a pituitary hormone primarily known for lactation but with metabolic effects. Normal range: under 25 ng/mL in women; under 20 ng/mL in men (non-pregnant). Elevated prolactin can cause galactorrhea (milk production unrelated to childbirth), amenorrhea (menstrual loss), decreased libido, erectile dysfunction, infertility, vision changes (from large tumor), and headaches. Causes of elevated prolactin: prolactinoma (pituitary tumor — most common cause of significant elevation), medications (antipsychotics like risperidone and haloperidol — major cause; antidepressants, antiemetics like metoclopramide, blood pressure meds like verapamil and methyldopa, opioids), hypothyroidism (TRH stimulates prolactin), pregnancy/breastfeeding (physiological), stress (modest elevation), macroprolactinemia (large prolactin molecules with reduced activity — test artifact), renal disease, liver disease. Connections to diabetes: prolactinoma may cause insulin resistance; antipsychotic medications cause both hyperprolactinemia and metabolic side effects (weight gain, diabetes risk); hyperprolactinemia causes hypogonadism affecting insulin sensitivity; direct metabolic effects modest. Treatment of prolactinoma (dopamine agonists like cabergoline) may improve insulin sensitivity. For most adults with diabetes, prolactin testing not routine. Tested when: hyperprolactinemia symptoms (galactorrhea, amenorrhea, ED, infertility), suspected pituitary tumor, evaluation of antipsychotic side effects. Treatment: dopamine agonists (cabergoline first-line) for prolactinomas — shrinks tumor and lowers prolactin in 80-90% of cases; surgery for tumors not responding to medication.

Prolactin Reference Ranges

Causes of Elevated Prolactin

• Prolactinoma: pituitary tumor producing prolactin; most common cause of significant elevation.
• Medications (major cause): antipsychotics (risperidone, haloperidol, fluphenazine), antidepressants (SSRIs occasionally), antiemetics (metoclopramide, prochlorperazine), blood pressure meds (verapamil, methyldopa), opioids, ranitidine (withdrawn).
• Hypothyroidism: TRH stimulates prolactin.
• Pregnancy and breastfeeding: physiological.
• Stress: modest elevation.
• Sleep, nipple stimulation: physiological.
• Macroprolactinemia: test artifact; benign.
• Renal disease: reduced clearance.
• Liver disease.
• Severe stress, vigorous exercise: temporary elevation.
• Polycystic ovary syndrome: modest elevation in some.

Symptoms of Hyperprolactinemia

• Women: galactorrhea (milk production not related to childbirth), amenorrhea or oligomenorrhea (missing/irregular periods), decreased libido, infertility, vaginal dryness.
• Men: decreased libido, erectile dysfunction, decreased sperm count, infertility, gynecomastia, occasionally galactorrhea.
• Both: headaches, vision changes (if large pituitary tumor), bone density loss with chronic untreated.
• Most adults with mild elevation are asymptomatic.
• Significant elevation (over 100): symptoms more common.

Connections to Diabetes

• Antipsychotic medications cause both hyperprolactinemia AND metabolic side effects (weight gain, diabetes).
• Adults with severe mental illness have higher diabetes rates partly from antipsychotic effects.
• Prolactinoma may cause insulin resistance.
• Hyperprolactinemia causes hypogonadism (low testosterone in men, low estrogen in women) — affects insulin sensitivity.
• Treatment with dopamine agonists may improve insulin sensitivity.
• Direct effects of prolactin on glucose metabolism modest.

Antipsychotics and Prolactin

• Many antipsychotics increase prolactin by blocking dopamine receptors.
• Highest prolactin elevation: risperidone, paliperidone, haloperidol, fluphenazine.
• Less prolactin elevation: olanzapine, quetiapine, clozapine.
• Minimal effect: aripiprazole (sometimes lowers).
• Sexual side effects from hyperprolactinemia.
• For adults with severe mental illness on antipsychotics: aripiprazole alternative for prolactin/sexual side effects.
• Discuss with prescriber if medication changes considered.

Prolactinoma Treatment

• Dopamine agonists (first-line): cabergoline (preferred — twice weekly), bromocriptine (older, more side effects).
• Shrink tumor in 80-90% of cases.
• Normalize prolactin in most.
• Side effects: nausea, headache, orthostatic hypotension.
• Cabergoline at high doses associated with cardiac valve issues — monitor with echo.
• Surgery: for adults not responding to medications.
• Radiation: for residual disease.
• Monitor with prolactin levels and MRI.
• Long-term endocrinology care.

When to Test Prolactin

• Galactorrhea (women without recent childbirth).
• Amenorrhea or irregular periods.
• Infertility evaluation.
• Erectile dysfunction or decreased libido.
• Suspected pituitary tumor (vision changes, persistent headaches).
• Antipsychotic medication side effects.
• Gynecomastia in men.
• Hypothyroidism diagnosis (test for prolactin too).
• Not routine for diabetes evaluation.

The Bottom Line

Prolactin is a pituitary hormone primarily known for lactation but with metabolic effects. Normal range: under 25 ng/mL in women; under 20 ng/mL in men (non-pregnant). Elevated prolactin can cause galactorrhea (milk production unrelated to childbirth), amenorrhea, decreased libido, erectile dysfunction, infertility, vision changes (large tumor), headaches. Causes of elevated prolactin: prolactinoma (pituitary tumor — most common cause of significant elevation), medications major cause (antipsychotics like risperidone and haloperidol; antidepressants; antiemetics like metoclopramide; blood pressure meds like verapamil and methyldopa; opioids), hypothyroidism (TRH stimulates prolactin), pregnancy/breastfeeding (physiological), stress, macroprolactinemia (test artifact; benign), renal disease, liver disease. Connections to diabetes: antipsychotic medications cause both hyperprolactinemia AND metabolic side effects (weight gain, diabetes); adults with severe mental illness have higher diabetes rates partly from antipsychotic effects. Prolactinoma may cause insulin resistance through hyperprolactinemia-induced hypogonadism affecting insulin sensitivity. Treatment with dopamine agonists may improve insulin sensitivity. Direct metabolic effects of prolactin modest. Testing: blood draw, ideally morning, after avoiding stress and physical activity. Repeat elevated levels — single elevation may not be meaningful. Symptoms in women: galactorrhea, amenorrhea/oligomenorrhea, decreased libido, infertility, vaginal dryness. Symptoms in men: decreased libido, erectile dysfunction, decreased sperm count, infertility, gynecomastia, occasional galactorrhea. Both: headaches, vision changes (large tumor), bone density loss with chronic untreated. Antipsychotics and prolactin: risperidone, paliperidone, haloperidol, fluphenazine cause highest elevation; aripiprazole minimal effect (sometimes lowers); aripiprazole alternative for adults with prolactin/sexual side effects on other antipsychotics. Prolactinoma treatment: dopamine agonists (first-line) — cabergoline (preferred, twice weekly) or bromocriptine; shrinks tumor in 80-90% of cases; normalizes prolactin in most. Side effects: nausea, headache, orthostatic hypotension; cabergoline at high doses associated with cardiac valve issues — monitor with echo. Surgery for non-responders. Long-term endocrinology care. For most adults with diabetes, prolactin testing not routine. Tested when: hyperprolactinemia symptoms (galactorrhea, amenorrhea, ED, infertility), suspected pituitary tumor (vision changes, persistent headaches), evaluation of antipsychotic side effects, gynecomastia in men, hypothyroidism diagnosis. See our broader diabetes detection guide for context.

Growth hormone (GH), also called somatotropin, is produced by the pituitary gland. GH stimulates growth in children, maintains tissue regeneration and body composition in adults, and affects metabolism by increasing insulin resistance and raising blood glucose. GH acts mainly through IGF-1 (insulin-like growth factor 1) produced by the liver. GH is released in pulses, especially during sleep — making single measurements unreliable. IGF-1 is the more reliable test because it reflects average GH activity. For diabetes: GH excess (acromegaly) commonly causes diabetes — 25-50% of adults with acromegaly develop diabetes; GH deficiency rare in adults except after pituitary surgery/radiation. Acromegaly is a disorder of excess growth hormone in adults, almost always from a benign pituitary tumor (adenoma). Effects on diabetes: GH increases insulin resistance, increases hepatic glucose production, may damage pancreatic beta cells. Other acromegaly features: gradual enlargement of hands, feet, jaw, brow (over years); coarsening facial features; joint pain; headaches; sleep apnea (often severe); vision changes; excessive sweating; cardiovascular issues. Rare disease (1 in 100,000+) but underdiagnosed because changes occur slowly. Testing methods: random GH usually NOT useful (pulsatile); IGF-1 most reliable measure (reflects average GH activity); oral glucose tolerance test with GH measurement is gold standard (healthy adults suppress GH to under 1 ng/mL after glucose load; acromegaly fails to suppress); MRI pituitary if biochemical tests confirm. For most adults with diabetes, growth hormone testing is not part of standard evaluation; ordered when acromegaly suspected. Treatment of acromegaly (surgery, medications, radiation) often reverses or improves diabetes.

Growth Hormone and Diabetes

• GH increases insulin resistance.
• GH stimulates hepatic glucose production.
• GH may damage pancreatic beta cells with chronic excess.
• Acromegaly (GH excess): 25-50% develop diabetes.
• “Diabetogenic” effect explains acromegaly-diabetes connection.
• Treating acromegaly often reverses or improves diabetes.
• GH deficiency rare in adults; usually after pituitary surgery/radiation.
• Adult GH deficiency can also affect body composition and metabolism.

Acromegaly Features (Develop Gradually Over Years)

• Enlargement of hands, feet, jaw, brow.
• Changes in shoe size, ring size, hat size.
• Coarsening facial features.
• Prognathism (jutting jaw).
• Wide tooth spaces.
• Deep voice (vocal cord thickening).
• Joint pain and arthritis.
• Headaches.
• Vision changes (tumor pressing on optic nerve).
• Sleep apnea (often severe).
• Excessive sweating (hyperhidrosis).
• Skin tags.
• Cardiovascular issues — hypertension, heart enlargement.
• New diabetes onset.
• Carpal tunnel syndrome.
• Erectile dysfunction in men.

Testing Methods for GH/IGF-1

IGF-1 Reference Ranges (by age)

Acromegaly Treatment Options

• Surgery: transsphenoidal resection of pituitary tumor; first-line for most cases.
• Somatostatin analogs: octreotide, lanreotide — suppress GH production.
• GH receptor antagonist: pegvisomant — blocks GH action.
• Dopamine agonists: cabergoline — modest benefit for some.
• Radiation: stereotactic radiosurgery; for residual disease.
• Combination therapy: often needed.
• Treatment goal: normalize IGF-1 and reduce tumor size.
• Treatment often reverses or improves diabetes.
• Long-term follow-up at endocrine center recommended.

When to Suspect Acromegaly in Diabetes

• Gradual changes in facial appearance (review old photos).
• Changes in shoe, ring, hat size over years.
• Severe sleep apnea.
• New diabetes with unusual features.
• Severe joint pain.
• Persistent headaches with vision changes.
• Excessive sweating.
• Carpal tunnel syndrome (especially bilateral).
• Family history of pituitary tumors.
• Skin tags and oily skin.
• If suggestive, order IGF-1 testing as initial screen.

GH Deficiency in Adults

• Rare — usually after pituitary surgery, radiation, or trauma.
• Symptoms: fatigue, decreased exercise tolerance, increased body fat (central), decreased muscle.
• Lower bone density.
• Mood changes.
• Affects insulin sensitivity (effects more variable).
• Treatment: GH replacement (somatropin) injection.
• Treatment specialized at endocrine centers.
• Not routinely tested for diabetes.

The Bottom Line

Growth hormone (GH), also called somatotropin, is produced by the pituitary gland. GH stimulates growth in children, maintains tissue regeneration and body composition in adults, and affects metabolism by increasing insulin resistance and raising blood glucose. GH acts mainly through IGF-1 (insulin-like growth factor 1) produced by the liver. GH is released in pulses, especially during sleep — making single measurements unreliable. IGF-1 is the more reliable test because it reflects average GH activity. For diabetes: GH excess (acromegaly) commonly causes diabetes — 25-50% of adults with acromegaly develop diabetes; GH deficiency rare in adults except after pituitary surgery/radiation. Acromegaly is a disorder of excess growth hormone in adults, almost always from a benign pituitary tumor (adenoma). Mechanism: GH increases insulin resistance, increases hepatic glucose production, may damage pancreatic beta cells. Acromegaly features (develop gradually over years): enlargement of hands, feet, jaw, brow; changes in shoe/ring/hat size; coarsening facial features; prognathism; deep voice; joint pain; headaches; vision changes; severe sleep apnea; excessive sweating; skin tags; cardiovascular issues; new diabetes onset; carpal tunnel syndrome. Rare disease (1 in 100,000+) but underdiagnosed because changes occur slowly — look at old photos to track gradual changes. Testing methods: random GH usually NOT useful (pulsatile); IGF-1 most reliable measure (age-adjusted ranges); oral glucose tolerance test with GH measurement is gold standard (healthy adults suppress GH to under 1 ng/mL after glucose load; acromegaly fails to suppress); MRI pituitary if biochemical tests confirm. Acromegaly treatment options: surgery (transsphenoidal resection — first-line), somatostatin analogs (octreotide, lanreotide), GH receptor antagonist (pegvisomant), dopamine agonists (cabergoline), radiation. Treatment often reverses or improves diabetes. When to suspect acromegaly in diabetes: gradual facial changes (review old photos), changes in shoe/ring/hat size over years, severe sleep apnea, severe joint pain, persistent headaches with vision changes, excessive sweating, carpal tunnel syndrome, skin tags, family history of pituitary tumors. If suggestive, order IGF-1 as initial screen. GH deficiency in adults is rare (usually after pituitary surgery/radiation); not routinely tested for diabetes. For most adults with type 2 diabetes, growth hormone testing is not part of standard evaluation; reserved for adults with suggestive features of acromegaly. Diagnosing acromegaly leads to specialized treatment that often resolves the associated diabetes. See our broader diabetes detection guide for context.

The estrogen test typically measures estradiol (E2) — the primary form of estrogen in reproductive-age women. Other estrogens include estrone (E1, more important after menopause) and estriol (E3, important in pregnancy). Estrogen testing uses include: evaluating menstrual irregularities, workup for PCOS or premature ovarian failure, confirming menopause, monitoring fertility treatment, evaluating estrogen-related conditions. Normal estradiol varies dramatically by menstrual cycle phase and menopause status. Reproductive-age women: 30-400 pg/mL depending on cycle phase. Post-menopausal: under 30 pg/mL typically. Estrogen affects diabetes through multiple mechanisms: improves insulin sensitivity in pre-menopausal women; declining estrogen during menopause worsens insulin resistance and increases T2D risk; affects fat distribution (premenopausal subcutaneous favorable; postmenopausal more visceral); affects lipid profile (favorable pre-menopause). Polycystic ovary syndrome (PCOS) characterized by relatively elevated androgens with insulin resistance — 50-70% of women with PCOS have insulin resistance; many develop type 2 diabetes. Hormone replacement therapy decisions in diabetes: WHI study showed HRT increased cardiovascular events in older women but “timing hypothesis” suggests within 10 years of menopause and under age 60 may be safer or beneficial. Women with diabetes may benefit from HRT for cardiovascular protection if started early in menopause; transdermal estradiol may be safer than oral. Discuss benefits and risks with healthcare provider. For women with diabetes navigating menopause: increased attention to glucose management needed.

Estradiol Reference Ranges

Estrogen and Diabetes Connection

• Estrogen improves insulin sensitivity in pre-menopausal women.
• Estrogen affects fat distribution — subcutaneous (favorable) vs visceral (harmful).
• Estrogen affects lipid profile favorably in pre-menopause.
• Declining estrogen during menopause worsens insulin resistance.
• Menopause increases T2D risk by 30-40% over 10 years.
• Adipose tissue produces some estrogen (aromatase).
• Obesity increases peripheral estrogen production in postmenopausal women.
• PCOS associates with relative androgen excess and insulin resistance.

Menopause and Diabetes

• Average menopause age: 51 years.
• Perimenopause: 4-10 years before final period; variable hormones.
• Menopause defined as 12 months without period.
• Insulin sensitivity decreases during/after menopause.
• Weight gain common — central fat distribution.
• Lipid profile worsens (LDL increases, HDL may decrease).
• Cardiovascular risk increases.
• For women with diabetes: closer monitoring needed.
• Strategies: continue exercise, manage weight, focus on whole foods, address sleep disruption from hot flashes.

PCOS and Diabetes

• 50-70% of women with PCOS have insulin resistance.
• 40-50% develop prediabetes; many develop type 2 diabetes by age 40.
• Symptoms: irregular periods, hirsutism, acne, polycystic ovaries on ultrasound, weight gain.
• Treatment: metformin (improves insulin sensitivity), GLP-1 agonists (newer for PCOS), lifestyle changes (weight loss).
• Hormonal options: combined oral contraceptives, anti-androgens (spironolactone).
• For weight loss: GLP-1 agonists particularly effective.
• Annual diabetes screening recommended.

Hormone Replacement Therapy (HRT) Considerations

• WHI study showed combined HRT increased cardiovascular events in older women (mean age 63).
• “Timing hypothesis” — HRT within 10 years of menopause and under age 60 may be safer.
• Transdermal estradiol (patch, gel) may be safer than oral — avoids first-pass liver metabolism.
• Combined estrogen + progestin (uterus intact) vs estrogen alone (after hysterectomy).
• Benefits: hot flashes, vaginal symptoms, bone density, possibly cardiovascular protection (if early).
• Risks: breast cancer (especially combined HRT), endometrial cancer (if estrogen alone with uterus), blood clots, stroke.
• Women with diabetes can use HRT — individualized decision.
• Discuss benefits/risks with healthcare provider.
• Lowest effective dose for shortest duration appropriate.

When to Test Estrogen

• Menstrual irregularities or amenorrhea.
• Confirming menopause (combined with FSH).
• PCOS workup.
• Premature ovarian failure suspicion.
• Fertility evaluation.
• Monitoring fertility treatment.
• Hormone replacement therapy decisions.
• Men with gynecomastia.
• Suspected adrenal or ovarian tumors.
• Not routinely needed for diabetes management in most women.

The Bottom Line

The estrogen test typically measures estradiol (E2) — the primary form of estrogen in reproductive-age women. Other estrogens include estrone (E1, more important after menopause) and estriol (E3, important in pregnancy). Estrogen testing uses include evaluating menstrual irregularities, PCOS workup, confirming menopause, monitoring fertility treatment, evaluating estrogen-related conditions. Normal estradiol varies dramatically by menstrual cycle phase: early follicular 30-100 pg/mL, late follicular 200-400, ovulation 200-400, luteal 100-300, postmenopause under 30, men under 40. Estrogen affects diabetes through multiple mechanisms: improves insulin sensitivity in pre-menopausal women; declining estrogen during menopause worsens insulin resistance and increases T2D risk by 30-40% over 10 years; affects fat distribution (premenopausal subcutaneous favorable; postmenopausal more visceral); affects lipid profile (favorable pre-menopause). Menopause and diabetes: insulin sensitivity decreases during/after menopause; weight gain common with central fat distribution; lipid profile worsens; cardiovascular risk increases. For women with diabetes navigating menopause: closer monitoring needed; continue exercise, manage weight, focus on whole foods, address sleep disruption from hot flashes. PCOS and diabetes: 50-70% of women with PCOS have insulin resistance; 40-50% develop prediabetes; many develop type 2 diabetes by age 40. Treatment: metformin (improves insulin sensitivity), GLP-1 agonists (newer, particularly effective for weight loss), lifestyle changes, hormonal options (combined OCs, anti-androgens). Annual diabetes screening recommended for PCOS. Hormone replacement therapy (HRT) decisions in diabetes: WHI study showed combined HRT increased cardiovascular events in older women but “timing hypothesis” suggests within 10 years of menopause and under age 60 may be safer; transdermal estradiol may be safer than oral; women with diabetes may benefit from HRT for cardiovascular protection if started early in menopause. Combined estrogen + progestin if uterus intact; estrogen alone if hysterectomy. Benefits: hot flashes, vaginal symptoms, bone density, possibly cardiovascular protection (if early). Risks: breast cancer, endometrial cancer (estrogen alone with uterus), blood clots, stroke. Individualized decision with healthcare provider. Estrogen testing not routinely needed for diabetes management; useful in specific clinical situations (menopause evaluation, PCOS workup, HRT decisions). For women with diabetes, understanding the hormonal-glucose connection helps anticipate changes through menopause and identifies treatable conditions like PCOS that often accompany insulin resistance. See our broader menopause and diabetes guide for context.

Low testosterone affects 30-50% of men with type 2 diabetes — much higher than general adult men (20%). Symptoms overlap with diabetes (fatigue, low libido, depression, weight gain) making testing important to distinguish. Causes of low T in diabetes: obesity (adipose tissue converts testosterone to estrogen), insulin resistance, inflammation, sleep apnea, opioid use, medications. Effects of low T: low energy, low libido, erectile dysfunction, muscle loss, increased body fat, depression, possibly worsened glucose control. Endocrine Society recommends screening men with type 2 diabetes who have symptoms. Testing methods: total testosterone (most common; normal 264-916 ng/dL; best drawn 7-10 AM when testosterone peaks; confirm low T with 2-3 morning measurements), free testosterone (biologically active form; normal 9-30 pg/mL; useful when SHBG abnormal), SHBG (high SHBG can falsely lower bioavailable testosterone). Treatment options for confirmed low T: topical gels (Androgel, Testim, Fortesta — daily application), patches (Androderm), intramuscular injections (cheapest option, every 2-3 weeks), pellets (Testopel — every 3-6 months), nasal gel (Natesto), oral (Jatenzo — newer). Treatment considerations: regular blood monitoring, prostate exam, cardiovascular monitoring, fertility impact (TRT suppresses sperm production). Recommend addressing modifiable factors first: weight loss (most effective — often raises testosterone significantly), sleep apnea treatment, depression treatment, opioid reduction. TRT may improve quality of life and modestly help diabetes management when modifiable factors addressed but T remains low.

Testosterone Reference Ranges

Why Low T Common in Type 2 Diabetes

• Obesity — adipose tissue converts testosterone to estrogen via aromatase.
• Insulin resistance — directly affects testicular function.
• Chronic inflammation — affects hypothalamic-pituitary-testicular axis.
• Sleep apnea (common in T2D) — reduces testosterone production.
• Sleep deprivation — even without apnea, reduces testosterone.
• Medications — opioids, glucocorticoids, statins (modest).
• Hyperglycemia itself may affect testosterone production.
• Combined effects: T2D men have 30-50% rate of low T.

Symptoms of Low T

• Low energy and fatigue.
• Reduced libido (sex drive).
• Erectile dysfunction.
• Reduced muscle mass.
• Increased body fat (especially abdominal).
• Depression and mood changes.
• Difficulty concentrating.
• Sleep disturbances.
• Hot flashes (rare but possible).
• Reduced facial/body hair (with prolonged severe deficiency).
• Many symptoms overlap with diabetes and depression.

Testosterone Replacement Therapy Options

Address Before TRT

• Weight loss — often raises testosterone significantly.
• Sleep apnea treatment (CPAP).
• Sleep adequacy improvement.
• Reduce alcohol consumption.
• Address depression.
• Review medications (opioids especially).
• Exercise — particularly resistance training.
• Glucose control improvement.
• Vitamin D adequacy.
• Zinc adequacy.
• Stress management.
• Smoking cessation.
• Many men’s testosterone normalizes with these interventions alone.

TRT Monitoring

• Total testosterone — target mid-normal range.
• Hematocrit — TRT can increase (donate blood if elevated).
• PSA — monitor for prostate concerns.
• Lipid panel — TRT can affect lipids.
• Cardiovascular monitoring — TRT effect on CV events debated.
• Initial monitoring: 3 months after starting.
• Ongoing: every 6-12 months.
• Prostate exam annually.
• Discuss fertility before starting (TRT suppresses sperm production).

Diabetes-Specific Considerations

• Weight loss is most effective intervention for low T in obese men.
• Treatment may modestly improve insulin sensitivity.
• Erectile dysfunction often improves with TRT (and with PDE5 inhibitors like sildenafil).
• Body composition changes can support diabetes management.
• TRT doesn’t directly lower A1C significantly.
• For men with diabetes and erectile dysfunction: address both diabetes and testosterone.
• Discuss screening with primary care or endocrinologist if symptomatic.

The Bottom Line

Low testosterone affects 30-50% of men with type 2 diabetes — much higher than general adult men. Symptoms overlap with diabetes (fatigue, low libido, depression, weight gain) making testing important. Causes in diabetes: obesity (adipose tissue converts testosterone to estrogen via aromatase), insulin resistance, inflammation, sleep apnea, sleep deprivation, opioid use, medications, hyperglycemia. Effects: low energy, low libido, erectile dysfunction, muscle loss, increased body fat, depression, possibly worsened glucose control. Endocrine Society recommends screening men with type 2 diabetes who have symptoms. Testing methods: total testosterone (normal 264-916 ng/dL; best drawn 7-10 AM when testosterone peaks; confirm low with 2-3 morning measurements), free testosterone (normal 9-30 pg/mL; useful when SHBG abnormal), SHBG (binding protein). Treatment options for confirmed low T: topical gels (Androgel, Testim — daily, $50-700/month), IM injections (testosterone cypionate every 2-3 weeks, cheapest at $30-100/month), pellets (Testopel every 3-6 months), patches (Androderm), nasal gel (Natesto), oral (Jatenzo). Address modifiable factors first: weight loss (most effective — often raises testosterone significantly), sleep apnea treatment with CPAP, depression treatment, opioid reduction, resistance exercise, glucose control improvement, vitamin D and zinc adequacy, stress management, smoking cessation. Many men’s testosterone normalizes with these interventions alone. TRT monitoring: total testosterone (target mid-normal), hematocrit (can increase with TRT — donate blood if elevated), PSA, lipid panel, initial monitoring 3 months then every 6-12 months, annual prostate exam. Discuss fertility before starting — TRT suppresses sperm production. Cardiovascular safety of TRT debated; recent studies suggest no clear increased risk in appropriately monitored adults. Treatment may modestly improve insulin sensitivity and body composition; doesn’t directly lower A1C significantly. For men with diabetes and erectile dysfunction: address both diabetes management and testosterone evaluation (PDE5 inhibitors like sildenafil also help ED). For men with type 2 diabetes and persistent fatigue, low libido, or depression after addressing modifiable factors, testosterone evaluation is reasonable and treatable in many cases. See our broader diabetes and low testosterone guide for context.

Cortisol is the stress hormone produced by adrenal glands that raises blood glucose by stimulating gluconeogenesis, increases insulin resistance, and promotes visceral fat accumulation. Chronic cortisol elevation worsens diabetes through multiple mechanisms. Cortisol testing methods: morning blood draw (8 AM; reflects peak cortisol; normal 6-20 mcg/dL), 24-hour urinary free cortisol (total daily production; normal less than 50 mcg/24 hours), late-night salivary cortisol (at-home test; should be very low at bedtime; elevation suggests Cushing’s), dexamethasone suppression test (healthy adults suppress own cortisol; failure suggests Cushing’s), and ACTH test (distinguishes pituitary vs adrenal causes). Causes of elevated cortisol: chronic stress, corticosteroid medications (prednisone, dexamethasone — most common overall), Cushing’s syndrome (1 in 100,000+ endogenous cases but underdiagnosed), severe depression. Cushing’s syndrome causes: pituitary tumor (Cushing’s disease, 80% of endogenous), adrenal tumor, ectopic ACTH (lung tumor), or long-term corticosteroid medication use. Cushing’s features: weight gain (abdomen, face “moon face,” upper back “buffalo hump”), thin skin, purple stretch marks, muscle weakness, hypertension, diabetes (50% develop), depression. Adults with treatment-resistant diabetes and Cushingoid features warrant testing. Chronic stress effects: higher fasting glucose, worsened insulin resistance, increased abdominal fat, higher A1C, poor adherence. Cortisol-lowering interventions: regular exercise, adequate sleep, mindfulness, deep breathing, social connection, treating depression if present.

Cortisol Testing Methods

Cortisol and Diabetes Connection

• Cortisol stimulates gluconeogenesis (glucose production in liver).
• Cortisol increases insulin resistance.
• Cortisol promotes visceral fat accumulation.
• Cortisol decreases peripheral glucose uptake.
• Cortisol slows wound healing.
• Cortisol increases appetite (especially for high-carb foods).
• Cortisol disrupts sleep, indirectly worsening glucose control.
• Chronic elevation: gradual worsening of diabetes.
• Cushing’s: dramatic glucose elevation; diabetes develops in 50% of cases.

Cushing’s Syndrome Features

• Weight gain — central obesity, “moon face,” “buffalo hump.”
• Thin, fragile skin that bruises easily.
• Purple/red stretch marks (striae) over abdomen, thighs.
• Muscle weakness, especially proximal (climbing stairs, rising from chair).
• Hypertension.
• Diabetes (50% of cases).
• Depression and mood changes.
• Menstrual irregularities.
• Erectile dysfunction in men.
• Osteoporosis.
• Slow wound healing.
• Excess hair growth in women (hirsutism).
• Acne and oily skin.
• Dorsocervical fat pad (“buffalo hump”).

Causes of Elevated Cortisol

• Exogenous (most common): long-term corticosteroid medications (prednisone, dexamethasone).
• Cushing’s disease: pituitary adenoma producing excess ACTH.
• Adrenal tumor: directly producing cortisol.
• Ectopic ACTH: lung or other tumor producing ACTH.
• Chronic stress: modest persistent elevation.
• Severe depression: pseudo-Cushing’s pattern.
• Alcoholism: pseudo-Cushing’s.
• Polycystic ovary syndrome: modest elevation.

Low Cortisol (Adrenal Insufficiency)

• Primary adrenal insufficiency (Addison’s disease) — adrenal gland failure.
• Secondary adrenal insufficiency — pituitary dysfunction.
• Sudden corticosteroid withdrawal.
• Symptoms: fatigue, weakness, weight loss, low blood pressure, skin darkening (Addison’s).
• Life-threatening adrenal crisis: vomiting, dehydration, low blood pressure, low blood sugar.
• Treatment: hydrocortisone replacement.
• Rare but important to recognize.

Stress Management for Cortisol

• Regular exercise — but not excessive (excessive raises cortisol).
• Adequate sleep (7-9 hours).
• Mindfulness meditation — reduces cortisol.
• Deep breathing exercises.
• Time in nature.
• Social connection.
• Therapy for chronic stress or anxiety.
• Limit caffeine — can elevate cortisol.
• Address sleep apnea if present.
• Treat depression if present.
• Yoga and tai chi — cortisol-lowering effects.

When to Test Cortisol

• Difficult-to-control diabetes despite adherence.
• Cushingoid features (weight gain pattern, striae, thin skin).
• Unexplained hypertension.
• Easy bruising.
• Muscle weakness.
• Mood changes.
• Long-term corticosteroid use (assess HPA axis).
• Symptoms of adrenal insufficiency (fatigue, low BP, weight loss).
• Pituitary tumor evaluation.
• Adrenal mass found on imaging.

The Bottom Line

Cortisol is the stress hormone produced by adrenal glands that raises blood glucose by stimulating gluconeogenesis, increases insulin resistance, and promotes visceral fat accumulation. Chronic cortisol elevation worsens diabetes through multiple mechanisms. Cortisol testing methods include morning blood draw (8 AM; normal 6-20 mcg/dL), 24-hour urinary free cortisol (normal less than 50 mcg/24 hours), late-night salivary cortisol (at-home test; should be very low at bedtime), 1 mg dexamethasone suppression test (failure to suppress suggests Cushing’s), and ACTH test (distinguishes causes). Causes of elevated cortisol: chronic stress, corticosteroid medications (prednisone — most common overall), Cushing’s syndrome (1 in 100,000+ endogenous cases but underdiagnosed), severe depression. Cushing’s syndrome causes: pituitary tumor (Cushing’s disease, 80% of endogenous), adrenal tumor, ectopic ACTH (lung tumor), or long-term corticosteroid medication use. Cushing’s features: weight gain (abdomen, face “moon face,” upper back “buffalo hump”), thin skin with easy bruising, purple stretch marks (striae), muscle weakness, hypertension, diabetes (50% develop), depression, menstrual irregularities, osteoporosis. Adults with treatment-resistant diabetes and Cushingoid features warrant testing — especially if features cluster together. Two of three first-line tests (24-h urine, late-night saliva, dexamethasone suppression) confirm Cushing’s diagnosis. Cortisol and diabetes: cortisol stimulates gluconeogenesis, increases insulin resistance, promotes visceral fat, decreases peripheral glucose uptake, slows wound healing, increases appetite for high-carb foods, disrupts sleep. Chronic stress effects on diabetes: higher fasting glucose, worsened insulin resistance, increased abdominal fat, higher A1C, poor adherence. Cortisol-lowering interventions: regular exercise (but not excessive), adequate sleep (7-9 hours), mindfulness meditation, deep breathing, time in nature, social connection, therapy for chronic stress, yoga and tai chi, limit caffeine, treat sleep apnea and depression if present. Low cortisol (adrenal insufficiency, Addison’s disease) is rare but life-threatening — symptoms include fatigue, weakness, weight loss, low blood pressure, skin darkening. Treatment with hydrocortisone replacement. When to test cortisol: difficult-to-control diabetes, Cushingoid features, unexplained hypertension, easy bruising, muscle weakness, long-term corticosteroid use, symptoms of adrenal insufficiency, pituitary or adrenal mass found on imaging. For adults with type 2 diabetes, cortisol evaluation is appropriate when diabetes control is unexpectedly poor or Cushingoid features are present. See our broader cortisol, stress and blood sugar guide for context.